Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 3Carcinoma, Transitional Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Head and Neck Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × disitamab vedotin × 90 days × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06966453 2026-04-21

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Pfizer

Phase 1/2 Recruiting
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡